Harmful versus beneficial effects of using short-term combined oral antidiabetic therapy: ‎An open label comparative clinical trial ‎

Background: Although oral antidiabetic drugs have many beneficial pleiotropic effects, they are ‎not free from adverse reactions that may interfere with glucose homeostasis. This study aimed ‎to assess the effects of as add- on-therapy to metformin, on metabolic, ‎cardiac, and renal determinants. ‎ Material methods: A total number seventy-eight type 2 diabetes (T2D) patients who ‎were treated metformin were allocated add-on-therapy for 12 weeks, glimepiride ‎‎(4mg/day, n=26), sitagliptin (100mg/day, n=28), canagliflozin (300mg/day, n=24). ‎Anthropometric measurements, glycemic indices, lipid, markers, determined ‎before initiation after treatment. Results: All three treatments significantly decreased triglyceride-to-glucose index, non-significantly altered serum uric acid-to creatinine. Glimepiride ‎significantly increased waist-to-height ratio (0.630±0.057 versus 0.640±0.057, p=0.040), ‎while it (0.650±0.058 0.640±0.054, ‎p=0.009, 0.650±0.041 0.630±0.044, p<0.001). Estimated glomerular filtration index- ‎epidemiology collaboration (ml/min/1.73m2) declined by using ‎‎(109.0±10.4 103.6±10.9, p=0.001), (106.1±12.4 103.3±15.0, ‎p=0.013). Conclusion: Careful selection agents can protect T2D ‎harmful events, particularly those related cardiovascular events function‎